CY1123144T1 - Επαγωγη καρδιακης αναγεννησης μe microrna - Google Patents

Επαγωγη καρδιακης αναγεννησης μe microrna

Info

Publication number
CY1123144T1
CY1123144T1 CY20201100046T CY201100046T CY1123144T1 CY 1123144 T1 CY1123144 T1 CY 1123144T1 CY 20201100046 T CY20201100046 T CY 20201100046T CY 201100046 T CY201100046 T CY 201100046T CY 1123144 T1 CY1123144 T1 CY 1123144T1
Authority
CY
Cyprus
Prior art keywords
microrna
induction
cardiac regeneration
regeneration
cardiac
Prior art date
Application number
CY20201100046T
Other languages
English (en)
Inventor
Edward E. Morrisey
Original Assignee
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsylvania filed Critical The Trustees Of The University Of Pennsylvania
Publication of CY1123144T1 publication Critical patent/CY1123144T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Η εφεύρεση αφορά συνθέσεις και μεθόδους για την προαγωγή του κυτταρικού πολλαπλασιασμού και της αποδιαφοροποίησης των κυττάρων σε βλαστοκύτταρα προκειμένου να προαχθεί η αναγέννηση του ιστού. Συγκεκριμένα η εφεύρεση αφορά την μεταβατική χορήγηση ενός microRNA (miR) ή μιμητικού αυτού για την προαγωγής του καρδιομυοκυτταρικού πολλαπλασιασμού και της καρδιακής αναγέννησης.
CY20201100046T 2014-05-16 2020-01-21 Επαγωγη καρδιακης αναγεννησης μe microrna CY1123144T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461994250P 2014-05-16 2014-05-16
PCT/US2015/030990 WO2015175889A1 (en) 2014-05-16 2015-05-15 Microrna induction of cardiac regeneration

Publications (1)

Publication Number Publication Date
CY1123144T1 true CY1123144T1 (el) 2021-10-29

Family

ID=54480744

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100046T CY1123144T1 (el) 2014-05-16 2020-01-21 Επαγωγη καρδιακης αναγεννησης μe microrna

Country Status (9)

Country Link
US (1) US10590419B2 (el)
EP (1) EP3143123B1 (el)
CY (1) CY1123144T1 (el)
DK (1) DK3143123T3 (el)
ES (1) ES2769030T3 (el)
MA (1) MA39990A (el)
PL (1) PL3143123T3 (el)
PT (1) PT3143123T (el)
WO (1) WO2015175889A1 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117898999A (zh) * 2017-03-31 2024-04-19 宾夕法尼亚大学理事会 用于心脏再生的组合物和方法
KR20200096610A (ko) * 2017-12-08 2020-08-12 유니버시티 오브 워싱톤 카르디올리핀 리모델링 및 심근세포 성숙을 검출 및 촉진하기 위한 방법 및 조성물 및 미토콘드리아 기능장애를 치료하는 관련 방법
US11179479B2 (en) 2018-01-05 2021-11-23 Animatus Biosciences, Llc Enhanced cardiomyocyte regeneration
US20220251552A1 (en) * 2019-03-25 2022-08-11 The Trustees Of The University Of Pennsylvania Regenerative Therapy Based on miRNA-302 Mimics for Enhancing Host Recovery from Pneumonia Caused by Streptococcus pneumoniae
EP3936616A1 (en) 2020-07-10 2022-01-12 Charité - Universitätsmedizin Berlin Microrna-targeted therapy for cardiac repair
CN112891619B (zh) * 2021-01-28 2021-10-26 四川大学 具有选择性抑制平滑肌细胞表型转化的基因洗脱涂层材料及其制备方法
WO2022202930A1 (ja) * 2021-03-23 2022-09-29 国立大学法人京都大学 組成物および医薬組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0264166B1 (en) 1986-04-09 1996-08-21 Genzyme Corporation Transgenic animals secreting desired proteins into milk
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US6756196B2 (en) 1999-06-28 2004-06-29 Millennium Pharmaceuticals, Inc. Molecules of the card-related protein family and uses thereof
EP2123759B1 (en) 2004-02-06 2014-01-15 Thermo Fisher Scientific Biosciences Inc. Stabilized RNAS as transfection controls and silencing reagents
US9683232B2 (en) 2007-12-10 2017-06-20 Kyoto University Efficient method for nuclear reprogramming
EP2229444B1 (en) 2008-01-16 2019-10-30 Shi-Lung Lin Generation of tumor-free embryonic stem-like pluripotent cells using inducible recombinant rna agents
US20100062534A1 (en) 2008-09-09 2010-03-11 The General Hospital Corporation Inducible lentiviral vectors for reprogramming somatic cells
US9115345B2 (en) 2010-04-19 2015-08-25 The Trustees Of The University Of Pennsylvania MicroRNA induction of pluripotential stem cells and uses thereof
CA2804791C (en) * 2010-07-08 2019-07-30 Duke University Direct reprogramming of cells to cardiac myocyte fate
US10557136B2 (en) * 2011-12-12 2020-02-11 Oncolmmunin Inc. In vivo delivery of oligonucleotides
ITRM20110685A1 (it) * 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci

Also Published As

Publication number Publication date
ES2769030T3 (es) 2020-06-24
EP3143123A4 (en) 2017-10-11
PT3143123T (pt) 2020-02-04
US10590419B2 (en) 2020-03-17
EP3143123A1 (en) 2017-03-22
WO2015175889A1 (en) 2015-11-19
DK3143123T3 (da) 2020-02-10
MA39990A (fr) 2015-11-19
US20170096671A1 (en) 2017-04-06
PL3143123T3 (pl) 2020-07-13
EP3143123B1 (en) 2019-11-27

Similar Documents

Publication Publication Date Title
CY1123144T1 (el) Επαγωγη καρδιακης αναγεννησης μe microrna
CY1123142T1 (el) Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων
CY1124663T1 (el) Αντιιικα παραγωγα ν4-υδροξυκυτιδινης
CL2018000457A1 (es) Anticuerpos anti-mesotelina completamente humanos y células con efecto inmune dirigido a la mesotelina
DK3143134T3 (da) Modificerede, naturlige dræberceller og anvendelser deraf
DK3434762T3 (da) Modificerede, naturlige dræberceller og naturlige dræbercellelinjer med øget cytotoksicitet
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
EP3701041A4 (en) METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH DEPLETED T-LYMPHOCYTES
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
TR201900776T4 (tr) Memeli hücre kültürlerinin hasadına ilişkin yöntem.
IL240881A0 (en) Expression of the t cell balance gene, preparations, materials and methods for its use
BR112016030965A2 (pt) Composições de veículo-anticorpo e métodos de fabricação e uso das mesmas
MX2017007196A (es) Fibroblastos de embrion de pollo inmortalizados.
AR095233A1 (es) Métodos y composiciones para el control de malezas
TR201904270T4 (tr) Tanımlı koşullar altında insan pluripotent kök hücrelerinin hematoendotelyal farklılaşması için yöntemler ve materyaller.
BR112017013481A2 (pt) material permeável a gás
BR112016016916A2 (pt) método de tratamento de angiodema hereditário (hae)
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
MA52542A (fr) Thérapie cellulaire adoptive
BR112016029630A2 (pt) derivados heteroaromáticos bicíclicos fundidos como inibidores de inibidores de cinase
TW201612308A (en) Collector architecture layout design
MY181994A (en) Immuno-modulatory progenitor (imp) cell
BR112017017886A2 (pt) gerando populações de células endoteliais arteriais
DK3200267T3 (da) Fastoxidbrændselscellestabel
MX2018014366A (es) Interfaces de proteina.